Clinical trial
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
NCT00610129 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2008
- Completion date
- January 31, 2010
- Enrollment
- 25 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic neuroendocrine tumors, neuroendocrine tumors